{"id":368,"date":"2024-03-11T12:53:18","date_gmt":"2024-03-11T12:53:18","guid":{"rendered":"https:\/\/admit:8890\/admit-therapeutics-participated-last-week-in-the-addf-investigators-day-and-ad-pd-2024-congress-held-in-lisbon\/"},"modified":"2025-09-04T06:20:58","modified_gmt":"2025-09-04T06:20:58","slug":"admit-therapeutics-participated-last-week-in-the-addf-investigators-day-and-ad-pd-2024-congress-held-in-lisbon","status":"publish","type":"post","link":"https:\/\/admit-therapeutics.com\/en\/admit-therapeutics-participated-last-week-in-the-addf-investigators-day-and-ad-pd-2024-congress-held-in-lisbon\/","title":{"rendered":"ADmit Therapeutics participated last week in the ADDF Investigators Day and AD\/PD 2024 congress held in Lisbon."},"content":{"rendered":"\n<p>Our CEO participated in the Alzheimer&#8217;s Drug Discovery Foundation Investigators Day to explain ADmit&#8217;s technology based on novel biomarkers in blood for the prognosis of Alzheimer&#8217;s disease. In addition, two posters were presented during the AD\/PD 2024 congress in Lisbon (Poster Shift1 0299: Analytical validation of blood mitochondrial methylcytosines for the prognosis of AD dementia progression at MCI stage, and Poster Shift1 0487: Diagnosis of Dementia with Lewy Bodies based on a NGS analysis of blood mitochondrial methylcytosines: a machine learning approach) by Marta Blanch, our product development manager. <br\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Our CEO participated in the Alzheimer&#8217;s Drug Discovery Foundation Investigators Day to explain ADmit&#8217;s technology based on novel biomarkers in blood for the prognosis of Alzheimer&#8217;s disease. In addition, two posters were presented during the AD\/PD 2024 congress in Lisbon (Poster Shift1 0299: Analytical validation of blood mitochondrial methylcytosines for the prognosis of AD dementia [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-368","post","type-post","status-publish","format-standard","hentry","category-sin-categorizar"],"acf":[],"_links":{"self":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/posts\/368","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/comments?post=368"}],"version-history":[{"count":1,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/posts\/368\/revisions"}],"predecessor-version":[{"id":369,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/posts\/368\/revisions\/369"}],"wp:attachment":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/media?parent=368"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/categories?post=368"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/tags?post=368"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}